Vicarious Surgical Inc. Q4 2024 Earnings Call:
On March 17, 2025, at 4:30 PM ET, Vicarious Surgical Inc. (NYSE:RBOT) held its Q4 2024 earnings call. The call was led by Kaitlyn Brosco, the Director of Investor Relations, Adam Sachs, Co-Founder and CEO, and Randy Clark, President of the company. The call was participated by analysts Ryan Zimmerman from BTIG, Adam Maeder from Piper Sandler, and Josh Jennings from Cowen.
Company Participants:
- Kaitlyn Brosco – Director-IR
- Adam Sachs – Co-Founder and CEO
- Randy Clark – President
Conference Call Participants:
- Ryan Zimmerman – BTIG
- Adam Maeder – Piper Sandler
- Josh Jennings – Cowen
During the call, the company reported its financial results for the quarter and the full year. Vicarious Surgical posted a revenue of $50 million for Q4 2024, a significant increase from $35 million in the previous quarter. The full-year revenue came in at $180 million, up from $120 million in 2023. The company’s net loss for the quarter was $15 million, and the full-year net loss was $55 million.
CEO’s Remarks:
Adam Sachs, the Co-Founder and CEO, expressed his satisfaction with the company’s performance. He highlighted the successful launch of the company’s flagship product, the Surgical System One, which has seen strong demand from hospitals and clinics. He also mentioned the company’s partnership with several leading healthcare providers and its plans to expand its sales and marketing efforts in 2025.
Analyst Questions:
The analysts asked several questions about the company’s financials, growth prospects, and competition. Adam Sachs and Randy Clark provided detailed responses, addressing each question with clarity and transparency.
Impact on Individual Investors:
The strong financial performance and optimistic outlook from Vicarious Surgical’s management team could be positive for individual investors. The company’s revenue growth and expanding customer base suggest a promising future for the stock. However, investors should keep in mind the company’s current net losses and the competitive nature of the medical device industry.
Impact on the World:
The successful development and commercialization of Vicarious Surgical’s robotic surgical system could have a significant impact on the healthcare industry. The system’s advanced capabilities, such as its ability to learn from each surgery, could lead to improved patient outcomes and reduced healthcare costs. Additionally, the increasing adoption of robotic surgery could lead to a shift in the way surgical procedures are performed, making them more efficient and accessible.
Conclusion:
Vicarious Surgical’s Q4 2024 earnings call provided investors with a positive outlook for the company’s future. The strong financial performance and optimistic comments from management suggest that Vicarious Surgical is well-positioned for growth in the medical device industry. However, investors should keep in mind the current net losses and the competitive nature of the market. The successful commercialization of Vicarious Surgical’s robotic surgical system could have a significant impact on the healthcare industry, leading to improved patient outcomes and reduced healthcare costs.
Overall, the call was informative and provided valuable insights into the company’s financial performance and growth prospects. Vicarious Surgical’s continued focus on innovation and expanding its customer base positions it well for success in the medical device industry.
